Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Grows By 38.2%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,568,740 shares, a growth of 38.2% from the December 15th total of 1,858,418 shares. Based on an average daily volume of 339,981 shares, the days-to-cover ratio is currently 7.6 days. Approximately 13.9% of the shares of the company are short sold. Approximately 13.9% of the shares of the company are short sold. Based on an average daily volume of 339,981 shares, the days-to-cover ratio is currently 7.6 days.

Hedge Funds Weigh In On Avalo Therapeutics

Several hedge funds have recently made changes to their positions in the business. BIT Capital GmbH acquired a new position in Avalo Therapeutics during the third quarter valued at $25,000. PFS Partners LLC grew its holdings in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Avalo Therapeutics during the second quarter worth $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth about $56,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $143,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AVTX shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Avalo Therapeutics in a research report on Thursday. BTIG Research reiterated a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a research report on Monday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Finally, Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.71.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock traded down $0.58 on Friday, hitting $15.06. The company had a trading volume of 358,390 shares, compared to its average volume of 260,900. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72. The company has a market cap of $278.76 million, a PE ratio of -2.81 and a beta of 0.84. The business has a 50-day simple moving average of $17.59 and a 200-day simple moving average of $13.12.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). On average, equities research analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.